SIGNIFICANCE OF NEUTROPHIL-LYMPHOCYTE RATIO IN DIFFERENT STAGES OF BREAST CANCER-Reference-Cited by-同舟云学术

SIGNIFICANCE OF NEUTROPHIL-LYMPHOCYTE RATIO IN DIFFERENT STAGES OF BREAST CANCER

Published:2021-12-01 Issue: Volume: Page:17-19
ISSN:
Container-title:INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH
language:en
Short-container-title:ijsr

Author:

J. Kumbhani Jay¹,Patel Mahesh²,Dhotre Sanjay³,Goswami Hansa M.⁴,Trivedi Purva⁵,Doshi Rishita⁶

Affiliation:

1. Third Year Resident Doctor, Department Of Pathology, B.j. Medical College, Ahmedabad, Gujarat.

2. Professor, Department Of Pathology, B.J. Medical College, Ahmedabad, Gujarat

3. Associate Professor, Department Of Pathology, B.J.Medical College, Ahmedabad, Gujarat

4. Professor and Head of Department, Department Of Pathology, B.J.Medical College, Ahmedabad,Gujarat.

5. Third Year Resident Doctor, Department Of Pathology, B.J.Medical College, Ahmedabad,Gujarat

6. Third Year Resident Doctor, Department Of Pathology, B.J.Medical College, Ahmedabad,Gujarat.

Abstract

The Neutrophil Lymphocyte Ratio (NLR) has a very signicant role in tumour genesis and progression. Despite newer molecular and genetic diagnostic testing in breast cancer diagnosis, the diagnostic and prognostic assessment of breast cancer currently relies on morphology and clinicopathological prognostic factors. Regularly used blood-based parameters, like neutrophil and lymphocyte counts, are relatively easy to assess, making them attractive parameters for an improved individualised risk assessment. The aim of this study is to explore the signicance of NLR in Breast cancer staging. Among the 60 cases studied, the majority(34) had Stage III breast cancer followed by Stage II breast cancer. Patients with a higher NLR had a higher breast cancer stage (P value <0.05).

Publisher

World Wide Journals

Reference14 articles.

1. Rosai and Ackerman’s Surgical Pathology.

2. Cortazar P., Geyer C.E. Pathological complete response in neoadjuvant treatment of breast cancer. Ann. Surg. Oncol. 2015;22:1441–1446. doi: 10.1245/s10434-015-4404-8.

3. Faria S.S., Fernandes P.C., Silva M.J.B., Lima V.C., Fontes W., Freitas-Junior R., Eterovic A.K., Forget P. The neutrophil-to-lymphocyte ratio: A narrative review. Ecancermedicalscience. 2016;10:702.

4. Wei B., Yao M., Xing C., Wang W., Yao J., Hong Y., Liu Y., Fu P. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: An updated systematic review and meta-analysis. OncoTargetsTher. 2016;9:5567–5575. doi: 10.2147/OTT.S108419.

5. Ou Q., Cheng J., Zhang L., Wang H., Wang W., Ma Y. The prognostic value of pretreatment neutrophil-to-lymphocyte ratio in breast cancer: Deleterious or advantageous? Tumor Biol. J. Int. Soc. Oncodev. Biol. Med. 2017;39:1010428317706214. doi: 10.1177/1010428317706214.